As the IFNβ release by irradiated cancer cells appears RT-dose dependent, we further investigated whether large RT fractions, similar to those used in the hypofractionated scRT schemes, may better exploit this important immunostimulatory pathway compared to smaller fractions applied in lcRT schedules. The gene discussed is IFNB1; the disease is cancer.